BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 24611626)

  • 21. Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: current treatments and future perspectives.
    Yilmaz M; Kantarjian H; Ravandi-Kashani F; Short NJ; Jabbour E
    Clin Adv Hematol Oncol; 2018 Mar; 16(3):216-223. PubMed ID: 29742077
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful second allogeneic stem cell transplantation in second remission induced by dasatinib in a child with Philadelphia chromosome positive acute lymphoblastic leukemia.
    Millot F; Cividin M; Brizard F; Chomel JC; Méchinaud F; Guilhot F
    Pediatr Blood Cancer; 2009 Jul; 52(7):891-2. PubMed ID: 19202569
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
    An X; Tiwari AK; Sun Y; Ding PR; Ashby CR; Chen ZS
    Leuk Res; 2010 Oct; 34(10):1255-68. PubMed ID: 20537386
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular remission after combination therapy with blinatumomab and ponatinib with relapsed/refractory Philadelphia chromosome-positive acute lymphocytic leukemia: two case reports.
    Yuda J; Yamauchi N; Kuzume A; Guo YM; Sato N; Minami Y
    J Med Case Rep; 2021 Mar; 15(1):164. PubMed ID: 33762010
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
    Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
    Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New approaches to the management of Philadelphia-chromosome-positive acute lymphocytic leukemia.
    Thomas DA; O'Brien S; Cortes J; Kantarjian H
    Curr Hematol Malig Rep; 2007 Jul; 2(3):183-9. PubMed ID: 20425368
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term molecular remission with persistence of BCR-ABL1-specific cytotoxic T cells following imatinib withdrawal in an elderly patient with Philadelphia-positive ALL.
    Riva G; Luppi M; Lagreca I; Barozzi P; Quadrelli C; Vallerini D; Zanetti E; Basso S; Forghieri F; Morselli M; Maccaferri M; Paolini A; Fantuzzi V; Messerotti A; Maffei R; Iacobucci I; Martinelli G; Marasca R; Narni F; Comoli P; Potenza L
    Br J Haematol; 2014 Jan; 164(2):299-302. PubMed ID: 24134676
    [No Abstract]   [Full Text] [Related]  

  • 28. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
    Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
    Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How should we treat older adults with Ph+ adult ALL and what novel approaches are being investigated?
    Wieduwilt MJ
    Best Pract Res Clin Haematol; 2017 Sep; 30(3):201-211. PubMed ID: 29050693
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
    Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
    N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment.
    Scheuring UJ; Pfeifer H; Wassmann B; Brück P; Gehrke B; Petershofen EK; Gschaidmeier H; Hoelzer D; Ottmann OG
    Leukemia; 2003 Sep; 17(9):1700-6. PubMed ID: 12970767
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pre-transplant imatinib-based therapy improves the outcome of allogeneic hematopoietic stem cell transplantation for BCR-ABL-positive acute lymphoblastic leukemia.
    Mizuta S; Matsuo K; Yagasaki F; Yujiri T; Hatta Y; Kimura Y; Ueda Y; Kanamori H; Usui N; Akiyama H; Miyazaki Y; Ohtake S; Atsuta Y; Sakamaki H; Kawa K; Morishima Y; Ohnishi K; Naoe T; Ohno R
    Leukemia; 2011 Jan; 25(1):41-7. PubMed ID: 20944676
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The development of agents targeting the BCR-ABL tyrosine kinase as Philadelphia chromosome-positive acute lymphoblastic leukemia treatment.
    Thomas X; Heiblig M
    Expert Opin Drug Discov; 2016 Nov; 11(11):1061-1070. PubMed ID: 27548716
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Imatinib mesylate, a selective inhibitor of BCR-ABL, in chronic myeloid leukemia.
    Carella AM
    Expert Rev Anticancer Ther; 2007 Mar; 7(3):249-51. PubMed ID: 17338645
    [No Abstract]   [Full Text] [Related]  

  • 35. Efficacy of dasatinib in conjunction with alpha-interferon for the treatment of imatinib-resistant and dasatinib-resistant Ph+ acute lymphoblastic leukemia.
    Visani G; Piccaluga P; Malagola M; Isidori A
    Leukemia; 2009 Sep; 23(9):1687-8. PubMed ID: 19421228
    [No Abstract]   [Full Text] [Related]  

  • 36. Philadelphia-positive Acute Lymphoblastic Leukemia: Do We Still Need Allogeneic Transplantation? Argument "Pro".
    Bachanova V
    Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S10-S15. PubMed ID: 28760293
    [No Abstract]   [Full Text] [Related]  

  • 37. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group.
    Yanada M; Takeuchi J; Sugiura I; Akiyama H; Usui N; Yagasaki F; Kobayashi T; Ueda Y; Takeuchi M; Miyawaki S; Maruta A; Emi N; Miyazaki Y; Ohtake S; Jinnai I; Matsuo K; Naoe T; Ohno R;
    J Clin Oncol; 2006 Jan; 24(3):460-6. PubMed ID: 16344315
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors.
    Abou Dalle I; Kantarjian HM; Short NJ; Konopleva M; Jain N; Garcia-Manero G; Garris R; Qiao W; Cortes JE; O'Brien S; Kebriaei P; Kadia T; Jabbour E; Ravandi F
    Am J Hematol; 2019 Dec; 94(12):1388-1395. PubMed ID: 31595534
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
    Abou Dalle I; Jabbour E; Short NJ; Ravandi F
    Curr Treat Options Oncol; 2019 Jan; 20(1):4. PubMed ID: 30675645
    [TBL] [Abstract][Full Text] [Related]  

  • 40. How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Fielding AK
    Blood; 2010 Nov; 116(18):3409-17. PubMed ID: 20656928
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.